Anavex Life Sciences has reported positive outcomes from its Phase 2b/3 trial of blarcamesine (Anavex®2-73), an investigational drug for Alzheimer’s disease. The study demonstrated statistically significant clinical efficacy, notably in slowing cognitive decline, while also reducing amyloid beta biomarkers—a hallmark of Alzheimer’s pathology.

Conducted across 52 medical centers in five countries, the 48-week randomized, double-blind, placebo-controlled trial involved 508 participants with early symptomatic Alzheimer’s disease, including mild cognitive impairment and mild dementia. Participants received either blarcamesine or a placebo via once daily oral capsules. Analysis of the study’s co-primary endpoints, which measured changes in cognitive function and brain atrophy, showed significant improvements in patients receiving the treatment compared to those on placebo.

Key findings included a marked improvement in the cognitive decline score (ADAS-Cog13) and clinical dementia rating (CDR-SB). Moreover, validated biomarkers, such as amyloid-beta pathology and MRI-based brain atrophy assessments, confirmed blarcamesine’s effectiveness in slowing disease progression. The drug reduced brain volume loss significantly, suggesting its potential as a neuroprotective agent.

The safety profile of blarcamesine was well-tolerated, with the most common adverse effect being transient dizziness, experienced by 35.8% of participants during the titration phase. The adverse events were typically mild to moderate in severity, further supporting the drug’s safety as a once daily oral dementia treatment.

According to Marwan Noel Sabbagh, MD, Professor of Neurology and Chairman of Anavex’s Scientific Advisory Board, the treatment represents an exciting new direction in targeting Alzheimer’s progression, with its convenient oral administration and excellent safety profile. Blarcamesine is among the first drugs to demonstrate efficacy in targeting neurodegeneration markers in patients with Alzheimer’s disease.

Christopher U. Missling, PhD, President and CEO of Anavex Life Sciences, emphasized the significance of these findings for the future of Alzheimer’s treatment, highlighting the potential for blarcamesine to offer a convenient and effective treatment option for patients in the early stages of the disease.

This study underscores Anavex Life Sciences’ dedication to advancing therapeutic options for neurodegenerative diseases, with blarcamesine leading the way as a promising once daily oral dementia treatment.